Advances in RAS Inhibition in Pancreatic Ductal Adenocarcinoma - Episode 3

The Current and Evolving Role of KRAS G12C and Pan-KRAS Inhibitors in Metastatic PDAC

,

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.